Wisconsin Public Radio reports that a Madison-area nonprofit received an HHS voucher for psilocybin research in major depression, potentially shortening FDA review time.
HHS voucher supports psilocybin research
Wisconsin Public Radio reported that, after an April executive order, a Madison-area nonprofit received an HHS voucher. According to Wisconsin Public Radio, the voucher was awarded for the nonprofit’s research into treating major depression with psilocybin. Wisconsin Public Radio described the recipient as one of three organizations nationwide to receive a voucher. In the source’s account, the April executive order came before the voucher was received. The report identifies the recipient as Madison-area but does not provide further location details in the supplied extract.
Potentially shorter FDA review
Wisconsin Public Radio said the vouchers reduce FDA review time. The source gave a before-and-after range: FDA review may move from six to 10 months to one or two months with a voucher. Wisconsin Public Radio tied the shorter timeframe to the voucher for the organization’s research. The report describes a potential reduction in review speed, rather than a specific schedule for when patients could receive medications. The six-to-10-month and one-to-two-month ranges are the review-time figures reported by Wisconsin Public Radio.
Patient access is not immediate
Wisconsin Public Radio cautioned that faster approval does not necessarily mean patients will receive medications right away. In the source’s account, the potential reduction in FDA review time and the timing of medication access are separate points. The supplied extract does not state that receiving the voucher makes treatment immediately available, and it gives no timing for when patients might receive medications.
The report focuses on research into treating major depression with psilocybin, the HHS voucher and the potential reduction in FDA review time, according to Wisconsin Public Radio. It does not offer additional information in the supplied extract about treatment availability or a patient-access timetable. The reported development is limited to the research voucher and review timeline described by Wisconsin Public Radio. All review-time figures in this item are those reported by Wisconsin Public Radio.
What this means for Wisconsin patients
For Wisconsin patients looking for treatment locally, this report concerns research and federal review timing, not a statement that medications will be received right away. The directory lists 47 published clinics in Wisconsin.
This is general information, not medical advice.
More Wisconsin reporting on treatment updates.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.